Background: There is no clinical trial that assesses the effect synbiotic supplementation on HRQOL in CF children. Considering the importance of HRQOL as an essential primary outcome and determinant of therapeutic benefit in chronic diseases like cystic fibrosis, the present clinical trial aimed to determine the efficacy of synbiotic supplementation on HRQOL in children with CF.
Methods: In the present double-blind randomized clinical trial, 40 CF children were randomly allocated to the two groups. The intervention group was supplemented with synbiotics supplements and the patients in the placebo group received maltodextrin for six months. Demographic data and information about antibiotic use were recorded using the questionnaire. The health-related quality of life was assessed using the Persian version of quality of life inventory questionnaires. Paired t-test and ANCOVA were used for statistical analysis.
Results: Totally, 36 participants completed the trial. The mean score of HRQOL was 76.34±17.33. There were no significant differences between synbiotic and placebo groups regarding baseline demographic and quality of life characteristics. Compared with baseline values, the mean total score and subscores of quality of life did not change significantly after synbiotic and placebo supplementation (p>0.05). Moreover, the results of ANCOVA showed that there were no significant differences between the two groups regarding the post-trial value of HRQOL total score and subscores.
Conclusion: According to results, six-month supplementation with synbiotic did not have a significant effect on the HRQOL in children with CF. However, further studies with larger sample sizes and using more disease-specific questionnaires are needed for a more precise conclusion.
The protocol of the study was registered at Iranian registry clinical trials (Registration code: IRCT2017011732004N1; Registration date: 2017-02-14).
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Posted 20 Aug, 2020
On 15 Oct, 2020
On 19 Aug, 2020
On 17 Aug, 2020
On 16 Aug, 2020
On 16 Aug, 2020
Invitations sent on 12 Aug, 2020
On 12 Aug, 2020
On 02 Aug, 2020
On 01 Aug, 2020
On 01 Aug, 2020
On 29 Jul, 2020
Received 27 Jul, 2020
On 26 Jul, 2020
Invitations sent on 23 Jul, 2020
On 13 Jul, 2020
On 12 Jul, 2020
On 12 Jul, 2020
On 08 Jul, 2020
Received 21 Jun, 2020
Received 21 Jun, 2020
On 06 Jun, 2020
Received 06 Jun, 2020
On 03 Jun, 2020
Invitations sent on 02 Jun, 2020
On 02 Jun, 2020
On 05 May, 2020
On 04 May, 2020
On 04 May, 2020
On 04 May, 2020
Posted 20 Aug, 2020
On 15 Oct, 2020
On 19 Aug, 2020
On 17 Aug, 2020
On 16 Aug, 2020
On 16 Aug, 2020
Invitations sent on 12 Aug, 2020
On 12 Aug, 2020
On 02 Aug, 2020
On 01 Aug, 2020
On 01 Aug, 2020
On 29 Jul, 2020
Received 27 Jul, 2020
On 26 Jul, 2020
Invitations sent on 23 Jul, 2020
On 13 Jul, 2020
On 12 Jul, 2020
On 12 Jul, 2020
On 08 Jul, 2020
Received 21 Jun, 2020
Received 21 Jun, 2020
On 06 Jun, 2020
Received 06 Jun, 2020
On 03 Jun, 2020
Invitations sent on 02 Jun, 2020
On 02 Jun, 2020
On 05 May, 2020
On 04 May, 2020
On 04 May, 2020
On 04 May, 2020
Background: There is no clinical trial that assesses the effect synbiotic supplementation on HRQOL in CF children. Considering the importance of HRQOL as an essential primary outcome and determinant of therapeutic benefit in chronic diseases like cystic fibrosis, the present clinical trial aimed to determine the efficacy of synbiotic supplementation on HRQOL in children with CF.
Methods: In the present double-blind randomized clinical trial, 40 CF children were randomly allocated to the two groups. The intervention group was supplemented with synbiotics supplements and the patients in the placebo group received maltodextrin for six months. Demographic data and information about antibiotic use were recorded using the questionnaire. The health-related quality of life was assessed using the Persian version of quality of life inventory questionnaires. Paired t-test and ANCOVA were used for statistical analysis.
Results: Totally, 36 participants completed the trial. The mean score of HRQOL was 76.34±17.33. There were no significant differences between synbiotic and placebo groups regarding baseline demographic and quality of life characteristics. Compared with baseline values, the mean total score and subscores of quality of life did not change significantly after synbiotic and placebo supplementation (p>0.05). Moreover, the results of ANCOVA showed that there were no significant differences between the two groups regarding the post-trial value of HRQOL total score and subscores.
Conclusion: According to results, six-month supplementation with synbiotic did not have a significant effect on the HRQOL in children with CF. However, further studies with larger sample sizes and using more disease-specific questionnaires are needed for a more precise conclusion.
The protocol of the study was registered at Iranian registry clinical trials (Registration code: IRCT2017011732004N1; Registration date: 2017-02-14).
Figure 1
Loading...